Europe Colorectal Cancer Treatment Market Size and Forecast (2021 - 2031)
The Europe colorectal cancer treatment market is projected to grow significantly, reaching an estimated US$ 6,501.1 million by 2031, up from US$ 5,280.9 million in 2024, reflecting a compound annual growth rate (CAGR) of 3.0% from 2025 to 2031. This growth is driven by a high disease burden, demographic changes, evolving clinical practices, and disparities in healthcare access across various European countries.
Colorectal cancer (CRC) is a major public health concern in Europe, being one of the most prevalent cancers and a leading cause of cancer-related deaths. Men are disproportionately affected, with CRC accounting for approximately 11.6% of all cancer deaths in the European Union (EU). According to GLOBOCAN 2022, Europe reported around 538,532 new CRC cases and 244,824 deaths, making it the second most common cancer diagnosis in the region.
Screening is a crucial strategy in combating CRC, with many Western and Northern European countries implementing organized screening programs for individuals aged 50 to 74. The fecal immunochemical test (FIT) is the most widely used screening method, followed by colonoscopy for positive results. Countries like Austria, the Czech Republic, and Germany have seen significant reductions in CRC incidence due to these programs, while nations without large-scale screening, such as Bulgaria and Estonia, have experienced rising incidence rates.
Surgical resection remains the primary treatment for early-stage CRC, with a growing trend towards minimally invasive techniques in well-resourced healthcare systems. The adoption of laparoscopic and robotic surgeries is increasing, providing benefits such as quicker recovery times. However, access to these advanced procedures can vary significantly based on a country's healthcare infrastructure and funding.
Recent advancements in systemic therapies emphasize personalized medicine, with the European Medicines Agency (EMA) playing a pivotal role in drug approvals. A notable development is the approval of fruquintinib (FRUZAQLA) in June 2024, a targeted therapy for previously treated metastatic CRC, marking a significant milestone in treatment options for this patient group.
Research and development efforts in Europe are focusing on innovative approaches, including targeted therapies for specific mutations and non-invasive liquid biopsies for disease monitoring. The EU's "Beating Cancer Plan" aims to address care inequalities and promote prevention, early diagnosis, and access to innovative treatments, demonstrating a commitment to improving patient outcomes across the region.
The market segmentation for colorectal cancer treatment in Europe includes various categories. By treatment type, the market is divided into Surgery, Chemotherapy, Immunotherapy, Targeted Therapy, and Others, with Surgery being the dominant segment in 2024. Age-wise, the market is segmented into Below 49 Years, 50 - 64 Years, and Above 65 Years, with the latter group holding the largest share. In terms of end users, Hospitals, Specialty Clinics, and Home Care are the primary segments, with Hospitals leading the market.
The regulatory landscape is evolving, with bodies like the EMA and the UK's MHRA facilitating access to novel therapies through initiatives such as the Cancer Medicines Pathfinder. This regulatory support is expected to enhance the pipeline of innovative treatments, including targeted agents and immunotherapy regimens, thereby improving patient access to precision medicine.
Country-wise, Germany is the largest market for colorectal cancer treatment in Europe, driven by a significant disease burden and advancements in clinical care. CRC represents about 11-12% of all new cancer cases in Germany, with around 33,000 new cases diagnosed annually. The country has seen a decline in CRC incidence and mortality rates over the past two decades, attributed to improved screening and treatment options. The five-year survival rate has also improved significantly, now estimated at 70-75%.
Germany's treatment protocols align with global standards, utilizing colonoscopy-guided polypectomy or surgery for early-stage disease, and adjuvant chemotherapy and biologics for metastatic cases. The country is also innovating in early detection methods, such as smartphone-based FIT tests, which have shown promising results in increasing screening uptake.
Emerging therapies, including combinations of existing treatments and novel immunotherapeutic approaches, are being explored in clinical trials. The German market is characterized by a robust research and development ecosystem, with numerous clinical trials and a focus on pharmaceutical innovation.
Key players in the Europe colorectal cancer treatment market include Bayer AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Co., Genentech Inc., Takeda Pharmaceutical Co. Ltd., Amgen Inc., Regeneron Pharmaceuticals Inc., Eli Lilly and Co., and Otsuka Holdings Co. Ltd. These companies are pursuing various strategies, including product innovation and mergers and acquisitions, to enhance their market presence and offer innovative solutions to patients.
Colorectal cancer (CRC) is a major public health concern in Europe, being one of the most prevalent cancers and a leading cause of cancer-related deaths. Men are disproportionately affected, with CRC accounting for approximately 11.6% of all cancer deaths in the European Union (EU). According to GLOBOCAN 2022, Europe reported around 538,532 new CRC cases and 244,824 deaths, making it the second most common cancer diagnosis in the region.
Screening is a crucial strategy in combating CRC, with many Western and Northern European countries implementing organized screening programs for individuals aged 50 to 74. The fecal immunochemical test (FIT) is the most widely used screening method, followed by colonoscopy for positive results. Countries like Austria, the Czech Republic, and Germany have seen significant reductions in CRC incidence due to these programs, while nations without large-scale screening, such as Bulgaria and Estonia, have experienced rising incidence rates.
Surgical resection remains the primary treatment for early-stage CRC, with a growing trend towards minimally invasive techniques in well-resourced healthcare systems. The adoption of laparoscopic and robotic surgeries is increasing, providing benefits such as quicker recovery times. However, access to these advanced procedures can vary significantly based on a country's healthcare infrastructure and funding.
Recent advancements in systemic therapies emphasize personalized medicine, with the European Medicines Agency (EMA) playing a pivotal role in drug approvals. A notable development is the approval of fruquintinib (FRUZAQLA) in June 2024, a targeted therapy for previously treated metastatic CRC, marking a significant milestone in treatment options for this patient group.
Research and development efforts in Europe are focusing on innovative approaches, including targeted therapies for specific mutations and non-invasive liquid biopsies for disease monitoring. The EU's "Beating Cancer Plan" aims to address care inequalities and promote prevention, early diagnosis, and access to innovative treatments, demonstrating a commitment to improving patient outcomes across the region.
The market segmentation for colorectal cancer treatment in Europe includes various categories. By treatment type, the market is divided into Surgery, Chemotherapy, Immunotherapy, Targeted Therapy, and Others, with Surgery being the dominant segment in 2024. Age-wise, the market is segmented into Below 49 Years, 50 - 64 Years, and Above 65 Years, with the latter group holding the largest share. In terms of end users, Hospitals, Specialty Clinics, and Home Care are the primary segments, with Hospitals leading the market.
The regulatory landscape is evolving, with bodies like the EMA and the UK's MHRA facilitating access to novel therapies through initiatives such as the Cancer Medicines Pathfinder. This regulatory support is expected to enhance the pipeline of innovative treatments, including targeted agents and immunotherapy regimens, thereby improving patient access to precision medicine.
Country-wise, Germany is the largest market for colorectal cancer treatment in Europe, driven by a significant disease burden and advancements in clinical care. CRC represents about 11-12% of all new cancer cases in Germany, with around 33,000 new cases diagnosed annually. The country has seen a decline in CRC incidence and mortality rates over the past two decades, attributed to improved screening and treatment options. The five-year survival rate has also improved significantly, now estimated at 70-75%.
Germany's treatment protocols align with global standards, utilizing colonoscopy-guided polypectomy or surgery for early-stage disease, and adjuvant chemotherapy and biologics for metastatic cases. The country is also innovating in early detection methods, such as smartphone-based FIT tests, which have shown promising results in increasing screening uptake.
Emerging therapies, including combinations of existing treatments and novel immunotherapeutic approaches, are being explored in clinical trials. The German market is characterized by a robust research and development ecosystem, with numerous clinical trials and a focus on pharmaceutical innovation.
Key players in the Europe colorectal cancer treatment market include Bayer AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Co., Genentech Inc., Takeda Pharmaceutical Co. Ltd., Amgen Inc., Regeneron Pharmaceuticals Inc., Eli Lilly and Co., and Otsuka Holdings Co. Ltd. These companies are pursuing various strategies, including product innovation and mergers and acquisitions, to enhance their market presence and offer innovative solutions to patients.
1. INTRODUCTION
1.1 Report Guidance
1.2 Market Segmentation
2. EXECUTIVE SUMMARY
2.1 Key Insights
2.2 Market Attractiveness
3. RESEARCH METHODOLOGY
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macroeconomic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country-level data:
5. EUROPE COLORECTAL CANCER TREATMENT MARKET – KEY MARKET DYNAMICS
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints:
6. COLORECTAL CANCER TREATMENT MARKET - EUROPE MARKET ANALYSIS
6.1 Europe Colorectal Cancer Treatment Market Revenue (US$ Million), 2024 – 2031
6.2 Europe Colorectal Cancer Treatment Market Forecast and Analysis
7. EUROPE COLORECTAL CANCER TREATMENT MARKET REVENUE ANALYSIS – BY TREATMENT
7.1 Surgery
7.1.1 Overview
7.1.2 Surgery: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
7.2 Chemotherapy
7.2.1 Overview
7.2.2 Chemotherapy: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
7.3 Immunotherapy
7.3.1 Overview
7.3.2 Immunotherapy: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
7.4 Targeted Therapy
7.4.1 Overview
7.4.2 Targeted Therapy: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
7.5 Others
7.5.1 Overview
7.5.2 Others: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
8. EUROPE COLORECTAL CANCER TREATMENT MARKET REVENUE ANALYSIS – BY AGE GROUP
8.1 Below 49 Years
8.1.1 Overview
8.1.2 Below 49 Years: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
8.2 50 - 64 Years
8.2.1 Overview
8.2.2 50 - 64 Years: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
8.3 Above 65 Years
8.3.1 Overview
8.3.2 Above 65 Years: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
9. EUROPE COLORECTAL CANCER TREATMENT MARKET REVENUE ANALYSIS – BY END USERS
9.1 Hospitals
9.1.1 Overview
9.1.2 Hospitals: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
9.2 Specialty Clinics
9.2.1 Overview
9.2.2 Specialty Clinics: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
9.3 Home Care
9.3.1 Overview
9.3.2 Home Care: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
9.4 Others
9.4.1 Overview
9.4.2 Others: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
10. EUROPE COLORECTAL CANCER TREATMENT MARKET – COUNTRY ANALYSIS
10.1 Europe
10.1.1 Europe Colorectal Cancer Treatment Market Revenue and Forecast and Analysis – by Country
10.1.1.1 Europe Colorectal Cancer Treatment Market Revenue and Forecast and Analysis – by Country
10.1.2.2 Germany: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
10.1.2.2.1 Germany: Europe Colorectal Cancer Treatment Market Share – by Treatment
10.1.2.2.2 Germany: Europe Colorectal Cancer Treatment Market Share – by Age Group
10.1.2.2.3 Germany: Europe Colorectal Cancer Treatment Market Share – by End Users
10.2.3.3 France: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
10.2.3.3.1 France: Europe Colorectal Cancer Treatment Market Share – by Treatment
10.2.3.3.2 France: Europe Colorectal Cancer Treatment Market Share – by Age Group
10.2.3.3.3 France: Europe Colorectal Cancer Treatment Market Share – by End Users
10.3.4.4 United Kingdom: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
10.3.4.4.1 United Kingdom: Europe Colorectal Cancer Treatment Market Share – by Treatment
10.3.4.4.2 United Kingdom: Europe Colorectal Cancer Treatment Market Share – by Age Group
10.3.4.4.3 United Kingdom: Europe Colorectal Cancer Treatment Market Share – by End Users
10.4.5.5 Italy: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
10.4.5.5.1 Italy: Europe Colorectal Cancer Treatment Market Share – by Treatment
10.4.5.5.2 Italy: Europe Colorectal Cancer Treatment Market Share – by Age Group
10.4.5.5.3 Italy: Europe Colorectal Cancer Treatment Market Share – by End Users
10.5.6.6 Spain: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
10.5.6.6.1 Spain: Europe Colorectal Cancer Treatment Market Share – by Treatment
10.5.6.6.2 Spain: Europe Colorectal Cancer Treatment Market Share – by Age Group
10.5.6.6.3 Spain: Europe Colorectal Cancer Treatment Market Share – by End Users
10.6.7.7 Rest of Europe: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
10.6.7.7.1 Rest of Europe: Europe Colorectal Cancer Treatment Market Share – by Treatment
10.6.7.7.2 Rest of Europe: Europe Colorectal Cancer Treatment Market Share – by Age Group
10.6.7.7.3 Rest of Europe: Europe Colorectal Cancer Treatment Market Share – by End Users
11 COMPETITIVE LANDSCAPE
11.1 Heat Map Analysis by Key Players
11.2 Company Positioning & Concentration
12 INDUSTRY LANDSCAPE
12.1 Overview
12.2 New Product Development
12.3 Merger and Acquisition
12.4 Other Strategic Developments
13 COMPANY PROFILES
13.1 Bayer AG
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Pfizer Inc
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Teva Pharmaceutical Industries Ltd
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Bristol-Myers Squibb Co
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Genentech Inc
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 Takeda Pharmaceutical Co Ltd
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 Amgen Inc
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 Regeneron Pharmaceuticals Inc
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 Eli Lilly and Co
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
13.10 Otsuka Holdings Co Ltd
13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments
14. APPENDIX
14.1 About The Insight Partners
1.1 Report Guidance
1.2 Market Segmentation
2. EXECUTIVE SUMMARY
2.1 Key Insights
2.2 Market Attractiveness
3. RESEARCH METHODOLOGY
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macroeconomic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country-level data:
5. EUROPE COLORECTAL CANCER TREATMENT MARKET – KEY MARKET DYNAMICS
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints:
6. COLORECTAL CANCER TREATMENT MARKET - EUROPE MARKET ANALYSIS
6.1 Europe Colorectal Cancer Treatment Market Revenue (US$ Million), 2024 – 2031
6.2 Europe Colorectal Cancer Treatment Market Forecast and Analysis
7. EUROPE COLORECTAL CANCER TREATMENT MARKET REVENUE ANALYSIS – BY TREATMENT
7.1 Surgery
7.1.1 Overview
7.1.2 Surgery: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
7.2 Chemotherapy
7.2.1 Overview
7.2.2 Chemotherapy: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
7.3 Immunotherapy
7.3.1 Overview
7.3.2 Immunotherapy: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
7.4 Targeted Therapy
7.4.1 Overview
7.4.2 Targeted Therapy: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
7.5 Others
7.5.1 Overview
7.5.2 Others: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
8. EUROPE COLORECTAL CANCER TREATMENT MARKET REVENUE ANALYSIS – BY AGE GROUP
8.1 Below 49 Years
8.1.1 Overview
8.1.2 Below 49 Years: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
8.2 50 - 64 Years
8.2.1 Overview
8.2.2 50 - 64 Years: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
8.3 Above 65 Years
8.3.1 Overview
8.3.2 Above 65 Years: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
9. EUROPE COLORECTAL CANCER TREATMENT MARKET REVENUE ANALYSIS – BY END USERS
9.1 Hospitals
9.1.1 Overview
9.1.2 Hospitals: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
9.2 Specialty Clinics
9.2.1 Overview
9.2.2 Specialty Clinics: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
9.3 Home Care
9.3.1 Overview
9.3.2 Home Care: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
9.4 Others
9.4.1 Overview
9.4.2 Others: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
10. EUROPE COLORECTAL CANCER TREATMENT MARKET – COUNTRY ANALYSIS
10.1 Europe
10.1.1 Europe Colorectal Cancer Treatment Market Revenue and Forecast and Analysis – by Country
10.1.1.1 Europe Colorectal Cancer Treatment Market Revenue and Forecast and Analysis – by Country
10.1.2.2 Germany: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
10.1.2.2.1 Germany: Europe Colorectal Cancer Treatment Market Share – by Treatment
10.1.2.2.2 Germany: Europe Colorectal Cancer Treatment Market Share – by Age Group
10.1.2.2.3 Germany: Europe Colorectal Cancer Treatment Market Share – by End Users
10.2.3.3 France: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
10.2.3.3.1 France: Europe Colorectal Cancer Treatment Market Share – by Treatment
10.2.3.3.2 France: Europe Colorectal Cancer Treatment Market Share – by Age Group
10.2.3.3.3 France: Europe Colorectal Cancer Treatment Market Share – by End Users
10.3.4.4 United Kingdom: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
10.3.4.4.1 United Kingdom: Europe Colorectal Cancer Treatment Market Share – by Treatment
10.3.4.4.2 United Kingdom: Europe Colorectal Cancer Treatment Market Share – by Age Group
10.3.4.4.3 United Kingdom: Europe Colorectal Cancer Treatment Market Share – by End Users
10.4.5.5 Italy: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
10.4.5.5.1 Italy: Europe Colorectal Cancer Treatment Market Share – by Treatment
10.4.5.5.2 Italy: Europe Colorectal Cancer Treatment Market Share – by Age Group
10.4.5.5.3 Italy: Europe Colorectal Cancer Treatment Market Share – by End Users
10.5.6.6 Spain: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
10.5.6.6.1 Spain: Europe Colorectal Cancer Treatment Market Share – by Treatment
10.5.6.6.2 Spain: Europe Colorectal Cancer Treatment Market Share – by Age Group
10.5.6.6.3 Spain: Europe Colorectal Cancer Treatment Market Share – by End Users
10.6.7.7 Rest of Europe: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
10.6.7.7.1 Rest of Europe: Europe Colorectal Cancer Treatment Market Share – by Treatment
10.6.7.7.2 Rest of Europe: Europe Colorectal Cancer Treatment Market Share – by Age Group
10.6.7.7.3 Rest of Europe: Europe Colorectal Cancer Treatment Market Share – by End Users
11 COMPETITIVE LANDSCAPE
11.1 Heat Map Analysis by Key Players
11.2 Company Positioning & Concentration
12 INDUSTRY LANDSCAPE
12.1 Overview
12.2 New Product Development
12.3 Merger and Acquisition
12.4 Other Strategic Developments
13 COMPANY PROFILES
13.1 Bayer AG
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Pfizer Inc
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Teva Pharmaceutical Industries Ltd
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Bristol-Myers Squibb Co
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Genentech Inc
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 Takeda Pharmaceutical Co Ltd
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 Amgen Inc
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 Regeneron Pharmaceuticals Inc
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 Eli Lilly and Co
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
13.10 Otsuka Holdings Co Ltd
13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments
14. APPENDIX
14.1 About The Insight Partners
LIST OF TABLES
Table 1. Europe Colorectal Cancer Treatment Market Segmentation
Table 3. Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Table 4. Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Treatment
Table 5. Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Age Group
Table 6. Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by End Users
Table 7. Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Country
Table 8. Germany: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Treatment
Table 9. Germany: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Age Group
Table 10. Germany: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by End Users
Table 11. France: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Treatment
Table 12. France: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Age Group
Table 13. France: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by End Users
Table 14. United Kingdom: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Treatment
Table 15. United Kingdom: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Age Group
Table 16. United Kingdom: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by End Users
Table 17. Italy: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Treatment
Table 18. Italy: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Age Group
Table 19. Italy: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by End Users
Table 20. Spain: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Treatment
Table 21. Spain: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Age Group
Table 22. Spain: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by End Users
Table 23. Rest of Europe: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Treatment
Table 24. Rest of Europe: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Age Group
Table 25. Rest of Europe: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by End Users
Table 26. Heat Map Analysis by Key Players
Table 1. Europe Colorectal Cancer Treatment Market Segmentation
Table 3. Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Table 4. Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Treatment
Table 5. Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Age Group
Table 6. Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by End Users
Table 7. Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Country
Table 8. Germany: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Treatment
Table 9. Germany: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Age Group
Table 10. Germany: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by End Users
Table 11. France: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Treatment
Table 12. France: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Age Group
Table 13. France: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by End Users
Table 14. United Kingdom: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Treatment
Table 15. United Kingdom: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Age Group
Table 16. United Kingdom: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by End Users
Table 17. Italy: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Treatment
Table 18. Italy: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Age Group
Table 19. Italy: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by End Users
Table 20. Spain: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Treatment
Table 21. Spain: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Age Group
Table 22. Spain: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by End Users
Table 23. Rest of Europe: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Treatment
Table 24. Rest of Europe: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Age Group
Table 25. Rest of Europe: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by End Users
Table 26. Heat Map Analysis by Key Players
LIST OF FIGURES
Figure 1. Europe Colorectal Cancer Treatment Market Segmentation – Country
Figure 4. Europe Colorectal Cancer Treatment Market – Key Market Dynamics
Figure 5. Impact Analysis of Drivers and Restraints
Figure 6. Europe Colorectal Cancer Treatment Market Revenue (US$ Million), 2024 – 2031
Figure 7. Europe Colorectal Cancer Treatment Market Share (%) – by Treatment, 2024 and 2031
Figure 8. Surgery: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 9. Chemotherapy: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 10. Immunotherapy: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 11. Targeted Therapy: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 12. Others: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 13. Europe Colorectal Cancer Treatment Market Share (%) – by Age Group, 2024 and 2031
Figure 14. Below 49 Years: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 15. 50 - 64 Years: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 16. Above 65 Years: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 17. Europe Colorectal Cancer Treatment Market Share (%) – by End Users, 2024 and 2031
Figure 18. Hospitals: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 19. Specialty Clinics: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 20. Home Care: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 21. Others: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 22. Europe Colorectal Cancer Treatment Market Breakdown by Key Countries, 2024 and 2031 (%)
Figure 23. Germany: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 24. France: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 25. United Kingdom: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 26. Italy: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 27. Spain: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 28. Rest of Europe: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 29. Company Positioning & Concentration
Figure 1. Europe Colorectal Cancer Treatment Market Segmentation – Country
Figure 4. Europe Colorectal Cancer Treatment Market – Key Market Dynamics
Figure 5. Impact Analysis of Drivers and Restraints
Figure 6. Europe Colorectal Cancer Treatment Market Revenue (US$ Million), 2024 – 2031
Figure 7. Europe Colorectal Cancer Treatment Market Share (%) – by Treatment, 2024 and 2031
Figure 8. Surgery: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 9. Chemotherapy: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 10. Immunotherapy: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 11. Targeted Therapy: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 12. Others: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 13. Europe Colorectal Cancer Treatment Market Share (%) – by Age Group, 2024 and 2031
Figure 14. Below 49 Years: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 15. 50 - 64 Years: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 16. Above 65 Years: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 17. Europe Colorectal Cancer Treatment Market Share (%) – by End Users, 2024 and 2031
Figure 18. Hospitals: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 19. Specialty Clinics: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 20. Home Care: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 21. Others: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 22. Europe Colorectal Cancer Treatment Market Breakdown by Key Countries, 2024 and 2031 (%)
Figure 23. Germany: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 24. France: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 25. United Kingdom: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 26. Italy: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 27. Spain: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 28. Rest of Europe: Europe Colorectal Cancer Treatment Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 29. Company Positioning & Concentration
